John L. Fox, MD, MHA

Closing out their discussion on cardiovascular disease in prostate cancer, experts share their hopes for future evolution of the treatment landscape.

Shared insight on the value of multidisciplinary care and its current state in cardiovascular disease and prostate cancer.

Maria Lopes, MD, MS, elucidates the potential for quality measures and coverage policies to incorporate cardiovascular disease (CVD) and improve outcomes in prostate cancer.

Experts share insight on the need for clinical or real-world evidence to further solidify cardiovascular disease risk as an actionable factor in prostate cancer.

Expert perspectives on factors that inform prostate cancer therapy selection while keeping cardiovascular disease in mind.

Continuing their discussion on cost of care in prostate cancer, experts reflect on how cardiovascular disease impacts risk-bearing practices and alternative payment models.

Shared insight on the impact that cardiovascular disease has on cost of care in prostate cancer.

Experts consider available professional society guidelines on prostate cancer and cardiovascular disease management.

A brief review of factors that may put patients with prostate cancer at increased risk for developing cardiovascular disease.

Focusing on available agents in prostate cancer, experts consider how androgen deprivation therapy impacts risk of cardiovascular disease.

A comprehensive review of the therapeutic classes available for patients with prostate cancer.

Shared insight on the correlation between prostate cancer and cardiovascular disease, with a focus on the attributes that increase a patient’s risk.

A broad look at the economic burden of prostate cancer and outlook in regard to survival within the current treatment landscape.

Expert perspectives on prostate cancer with deference to clinical presentations, diagnosis, and prognosis.

Cliff Goodman, PhD, moderated a panel discussion on the Implications of Healthcare Reform: 'No' Will Be Heard.

How can pharmaceutical companies adapt to a changing environment? Are they the source of the problem, or have they simply responded to US Food and Drug Administration mandates?

A lively discussion on Foundation Medicine's approach to creating genomic profiles.

The final panel of the conference analyzes the role of the industry in healthcare, including panelists' observations on topics such as innovation. Mr Gamble, for instance, offers his insights as to how groups like the Community Oncology Alliance are working with the industry to drive the message about the quality and the value component throughout all the stakeholders. Dr Fox provides perspective on how payers can offer valuable partnerships throughout the industry, including those with pharmaceutical companies.

Mr Klein leads another discussion with Michael Kolodjiez, MD, Lee N. Newcomer, MD, MHA, John L. Fox, MD, MHA, and Jerry Conway. The panel responds to whether there are gaps in targeted gene analyses. They also discuss other issues including bioinformatics, and how payers, providers, and pharmacists might collaborate on improving care through genetic sequencing.

Implications of Healthcare Reform: 'No' Will Be Heard is led by Cliff Goodman, PhD, in a panel discussion featuring A. Mark Fendrick, MD, co-editor in chief of The American Journal of Managed Care, John L. Fox, MD, MHA, and Ira M. Klein, MD, MBA, FACP. The panelists determine what it means when a patient says no.